Latest & greatest articles for pneumonia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pneumonia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pneumonia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pneumonia

1. Ceftolozane/tazobactam (Zerbaxa) - hospital acquired pneumonia, including ventilator-associated pneumonia

Ceftolozane/tazobactam (Zerbaxa) - hospital acquired pneumonia, including ventilator-associated pneumonia Published 09 December 2019 1 Statement of advice SMC2256 ceftolozane / tazobactam 1g/0.5g powder for concentrate for solution for infusion (Zerbaxa®) Merck Sharp & Dohme Limited 8 November 2019 ADVICE: in the absence of a submission from the holder of the marketing authorisation ceftolozane / tazobactam (Zerbaxa®) is not recommended for use within NHSScotland. Indication under review (...) : In adults for the treatment of hospital acquired pneumonia, including ventilator-associated pneumonia. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium and was arrived at after careful consideration

2019 Scottish Medicines Consortium

2. Lefamulin (Xenleta) - community-acquired bacterial pneumonia

Lefamulin (Xenleta) - community-acquired bacterial pneumonia Drug Approval Package: XENLETA U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: XENLETA Company: Nabriva Therapeutics Application Number: 211672, 211673 Approval Date: 08/19/2019 (211672) (211673) Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF

2019 FDA - Drug Approval Package

3. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America

Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America Background: This document provides evidence-based clinical practice guidelines on the management of adult patients with community-acquired pneumonia.Methods: A multidisciplinary panel conducted pragmatic systematic reviews of the relevant research and applied Grading of Recommendations, Assessment, Development (...) and additional management decisions.Conclusions: The panel formulated and provided the rationale for recommendations on selected diagnostic and treatment strategies for adult patients with community-acquired pneumonia.

2019 EvidenceUpdates

4. The DRIP Score to Evaluate or Drug Resistant Organisms in Pneumonia

The DRIP Score to Evaluate or Drug Resistant Organisms in Pneumonia The DRIP Score to Evaluate or Drug Resistant Organisms in Pneumonia | Emergency Medicine | Washington University in St. Louis Open Menu Back Close Menu Search for: Loading... Welcome Our Team Sections Education Alumni Research ECRC Journal Club Events Jermyn Lectures Open Search Vignette You are moonlighting in your busy local community emergency department one afternoon when you encounter Mrs. P, a 67-year-old patient who (...) was sent in from her nursing home with concern for pneumonia. She reports three days of a productive cough, fever to 38.4 °C, and mild shortness of breath with exertion. She denies chest pain, vomiting, or diarrhea. She has a history of end-stage renal disease, for which she has been on hemodialysis three days a week for the last five years. In addition, she has a history of hypertension and non-insulin dependent diabetes. Her last hospital admission was for leg cellulitis after minor trauma

2019 Washington University Emergency Medicine Journal Club

5. Are Corticosteroids Beneficial in the Treatment of Community-Acquired Pneumonia?

Are Corticosteroids Beneficial in the Treatment of Community-Acquired Pneumonia? Are Corticosteroids Beneficial in the Treatment of Community-Acquired Pneumonia? - Annals of Emergency Medicine Email/Username: Password: Remember me Search Terms Search within Search Share this page Access provided by Volume 74, Issue 1, Pages e1–e3 Are Corticosteroids Beneficial in the Treatment of Community-Acquired Pneumonia? x Thomas Seagraves , MD (EBEM Commentator) , x Michael Gottlieb , MD (EBEM Commentator (...) ) Department of Emergency Medicine, Rush University Medical Center, Chicago, IL DOI: | Publication History Published online: June 21, 2018 Expand all Collapse all Article Outline Take-Home Message For adult patients with severe community-acquired pneumonia, corticosteroids reduce morbidity and mortality. For pediatric patients and adults with nonsevere community-acquired pneumonia, corticosteroids appear to reduce morbidity, but not mortality. Methods Data Sources The authors searched the Cochrane Acute

2019 Annals of Emergency Medicine Systematic Review Snapshots

6. Do Corticosteroids Benefit Patients With Influenza Pneumonia?

Do Corticosteroids Benefit Patients With Influenza Pneumonia? Do Corticosteroids Benefit Patients With Influenza Pneumonia? - Annals of Emergency Medicine Email/Username: Password: Remember me Search Terms Search within Search Share this page To read this article in full, please review your options for gaining access at the bottom of the page. Article in Press Do Corticosteroids Benefit Patients With Influenza Pneumonia? x Michael Gottlieb , MD (EBEM Commentator) , x Thomas Seagraves , MD (EBEM (...) Commentator) , x Stephen R. Gore , MD (EBEM Commentator) Department of Emergency Medicine, Rush University Medical Center, Chicago, IL DOI: Publication History Published online: July 23, 2019 To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. Among patients with influenza pneumonia, corticosteroids are associated with increased mortality, longer length of stay in the ICU, and higher rates of secondary infection, although there are no data from

2019 Annals of Emergency Medicine Systematic Review Snapshots

7. Pneumonia in the Immunocompetent Child.

Pneumonia in the Immunocompetent Child. New 2019 ACR Appropriateness Criteria ® 1 Pneumonia in the Immunocompetent Child American College of Radiology ACR Appropriateness Criteria ® Pneumonia in the Immunocompetent Child Variant 1: Child. 3 months of age and older. Immunocompetent. Suspected uncomplicated community- acquired pneumonia in a well-appearing child who does not require hospitalization. Initial imaging. Procedure Appropriateness Category Relative Radiation Level Radiography chest (...) Usually Not Appropriate ? CT chest with IV contrast Usually Not Appropriate ???? CT chest without and with IV contrast Usually Not Appropriate ???? CT chest without IV contrast Usually Not Appropriate ???? MRI chest without and with IV contrast Usually Not Appropriate O MRI chest without IV contrast Usually Not Appropriate O US chest Usually Not Appropriate O Variant 2: Child. 3 months of age and older. Immunocompetent. Community-acquired pneumonia that does not respond to initial outpatient treatment

2019 American College of Radiology

8. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America

Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America | American Journal of Respiratory and Critical Care Medicine Cookies Notification This site uses cookies. By continuing to browse (...) the site you are agreeing to our use of cookies. Search Menu Connect With Us Search in: American Journal of Respiratory and Critical Care Medicine > > Abstract Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America x Joshua P. Metlay , x Grant W. Waterer , x Ann C. Long , x Antonio Anzueto , x Jan Brozek , x Kristina Crothers , x Laura A. Cooley , x Nathan C. Dean , x

2019 American Thoracic Society

9. Community-Acquired Pneumonia (CAP) in Adults

Community-Acquired Pneumonia (CAP) in Adults Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America | American Journal of Respiratory and Critical Care Medicine Cookies Notification This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Search Menu Connect With Us Search in: American Journal of Respiratory and Critical Care (...) Medicine > > Abstract Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America x Joshua P. Metlay , x Grant W. Waterer , x Ann C. Long , x Antonio Anzueto , x Jan Brozek , x Kristina Crothers , x Laura A. Cooley , x Nathan C. Dean , x Michael J. Fine , x Scott A. Flanders , x Marie R. Griffin , x Mark L. Metersky , x Daniel M. Musher , x Marcos I. Restrepo , and x Cynthia G

2019 Infectious Diseases Society of America

10. Pneumonia (hospital-acquired): antimicrobial prescribing

Pneumonia (hospital-acquired): antimicrobial prescribing Pneumonia (hospital-acquired): Pneumonia (hospital-acquired): antimicrobial prescribing antimicrobial prescribing NICE guideline Published: 16 September 2019 www.nice.org.uk/guidance/ng139 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after (...) be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Pneumonia (hospital-acquired): antimicrobial prescribing (NG139) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

11. Pneumonia (community-acquired): antimicrobial prescribing

Pneumonia (community-acquired): antimicrobial prescribing Pneumonia ( Pneumonia (community-acquired): community-acquired): antimicrobial prescribing antimicrobial prescribing NICE guideline Published: 16 September 2019 www.nice.org.uk/guidance/ng138 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived (...) be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Pneumonia (community-acquired): antimicrobial prescribing (NG138) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

12. Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial. (PubMed)

Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial. New antibacterials are needed to treat community-acquired bacterial pneumonia (CABP) because of growing antibacterial resistance and safety concerns with standard care.To evaluate the efficacy and adverse events of a 5-day oral lefamulin regimen in patients with CABP.A phase 3, noninferiority randomized clinical trial conducted at 99 sites (...) in 19 countries that included adults aged 18 years or older with a Pneumonia Outcomes Research Team (PORT) risk class of II, III, or IV; radiographically documented pneumonia; acute illness; 3 or more CABP symptoms; and 2 or more vital sign abnormalities. The first patient visit was on August 30, 2016, and patients were followed up for 30 days; the final follow-up visit was on January 2, 2018.Patients were randomized 1:1 to receive oral lefamulin (600 mg every 12 hours for 5 days; n = 370

2019 JAMA

13. Excess Antibiotic Treatment Duration and Adverse Events in Patients Hospitalized With Pneumonia: A Multihospital Cohort Study. (PubMed)

Excess Antibiotic Treatment Duration and Adverse Events in Patients Hospitalized With Pneumonia: A Multihospital Cohort Study. Randomized trials demonstrate no benefit from antibiotic treatment exceeding the shortest effective duration.To examine predictors and outcomes associated with excess duration of antibiotic treatment.Retrospective cohort study.43 hospitals in the Michigan Hospital Medicine Safety Consortium.6481 general care medical patients with pneumonia.The primary outcome (...) was the rate of excess antibiotic treatment duration (excess days per 30-day period). Excess days were calculated by subtracting each patient's shortest effective (expected) treatment duration (based on time to clinical stability, pathogen, and pneumonia classification [community-acquired vs. health care-associated]) from the actual duration. Negative binomial generalized estimating equations (GEEs) were used to calculate rate ratios to assess predictors of 30-day rates of excess duration. Patient outcomes

2019 Annals of Internal Medicine

14. Diagnostic accuracy of lung ultrasound performed by novice versus advanced sonographers for pneumonia in children: A systematic review and meta-analysis

Diagnostic accuracy of lung ultrasound performed by novice versus advanced sonographers for pneumonia in children: A systematic review and meta-analysis Childhood pneumonia is a leading cause of mortality worldwide. Growing evidence suggests that lung ultrasound (LUS) may be a reliable diagnostic alternative to chest x-ray for childhood pneumonia. However, it is unclear whether sonographer experience affects the diagnostic accuracy of LUS. We summarize the diagnostic accuracy of LUS (...) for pneumonia and compare the performance between novice and advanced sonographers with a systematic review and meta-analysis.We searched PubMed and EMBASE from inception to February 2018 for eligible studies that evaluated the utility of LUS in children suspected of having pneumonia against the reference standard of either imaging results alone or a combination of clinical, laboratory, and imaging results. We reported the study using the Preferred Reporting Items for a Systematic Review and Meta-analysis

2019 EvidenceUpdates

15. Effectiveness of a Bundled Intervention Including Adjunctive Corticosteroids on Outcomes of Hospitalized Patients With Community-Acquired Pneumonia: A Stepped-Wedge Randomized Clinical Trial

Effectiveness of a Bundled Intervention Including Adjunctive Corticosteroids on Outcomes of Hospitalized Patients With Community-Acquired Pneumonia: A Stepped-Wedge Randomized Clinical Trial Community-acquired pneumonia remains a leading cause of hospitalization, mortality, and health care costs worldwide. Randomized clinical trials support the use of adjunctive corticosteroids, early progressive mobilization, antibiotic switching rules, and dietary interventions in improving outcomes. However (...) hospitals in Melbourne, Australia, among a consecutive sample of patients with community-acquired pneumonia. The primary analysis and preparation of results took place between May 14 and November 25, 2018.Treating clinical teams were advised to prescribe prednisolone acetate, 50 mg/d, for 7 days (in the absence of any contraindication) and de-escalate from parenteral to oral antibiotics according to standardized criteria. Algorithm-guided early mobilization and malnutrition screening and treatment were

2019 EvidenceUpdates

16. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. (PubMed)

Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Pneumonia is the leading cause of death among children younger than 5 years. In this study, we estimated causes of pneumonia in young African and Asian children, using novel analytical methods applied to clinical and microbiological findings.We did a multi-site, international case-control study in nine study sites in seven countries (...) : Bangladesh, The Gambia, Kenya, Mali, South Africa, Thailand, and Zambia. All sites enrolled in the study for 24 months. Cases were children aged 1-59 months admitted to hospital with severe pneumonia. Controls were age-group-matched children randomly selected from communities surrounding study sites. Nasopharyngeal and oropharyngeal (NP-OP), urine, blood, induced sputum, lung aspirate, pleural fluid, and gastric aspirates were tested with cultures, multiplex PCR, or both. Primary analyses were restricted

Full Text available with Trip Pro

2019 Lancet

17. XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial

XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial To investigate whether XueBiJing injection improves clinical outcomes in critically ill patients with severe community-acquired pneumonia.Prospective, randomized, controlled study.Thirty-three hospitals in China.A total of 710 adults 18-75 years old with severe community-acquired pneumonia.Participants in the XueBiJing group received XueBiJing, 100 mL, q12 hours (...) , and the control group received a visually indistinguishable placebo.The primary outcome was 8-day improvement in the pneumonia severity index risk rating. Secondary outcomes were 28-day mortality rate, duration of mechanical ventilation and total duration of ICU stay. Improvement in the pneumonia severity index risk rating, from a previously defined endpoint, occurred in 203 (60.78%) participants receiving XueBiJing and in 158 (46.33%) participants receiving placebo (between-group difference [95% CI], 14.4

Full Text available with Trip Pro

2019 EvidenceUpdates

18. Validity of SMART-COP score in prognosis and severity of community acquired pneumonia in the emergency department

Validity of SMART-COP score in prognosis and severity of community acquired pneumonia in the emergency department Determining prognosis in community acquired pneumonia (CAP), is very important. Many scores are introduced up to now for prediction of pneumonia prognosis like SMART-COP.To evaluate validity of SMART-COP score in prognosis and severity of CAP in emergency department (ED).All patients older than 18 years old with clinical suspicion of CAP (meeting the inclusion criteria), were

2019 EvidenceUpdates

19. Guideline-Based Clinical Assessment Versus Procalcitonin-Guided Antibiotic Use in Pneumonia: A Pragmatic Randomized Trial

Guideline-Based Clinical Assessment Versus Procalcitonin-Guided Antibiotic Use in Pneumonia: A Pragmatic Randomized Trial Efforts to reduce unnecessary and unnecessarily long antibiotic treatment for community-acquired pneumonia have been attempted through use of procalcitonin and through guidelines based on serial clinical assessment. Our aim is to compare guideline-based clinical assessment- and procalcitonin algorithm-guided antibiotic use among patients with community-acquired pneumonia.We (...) performed a pragmatic, randomized, multicenter trial from November 2012 to April 2015 at 12 French hospitals. We included emergency department (ED) patients older than 18 years with community-acquired pneumonia. Patients were randomly assigned to either the procalcitonin-guided or clinical assessment group. In accordance with past studies, we hypothesized that serial clinical assessment would be superior to procalcitonin-guided care. The primary outcome was antibiotic duration, and secondary outcomes

2019 EvidenceUpdates

20. Should HIV-uninfected patients with Pneumocystis pneumonia be treated with corticosteroids?

Should HIV-uninfected patients with Pneumocystis pneumonia be treated with corticosteroids? Chiefs’ Inquiry Corner – March 17th, 2019 – Clinical Correlations Search Chiefs’ Inquiry Corner – March 17th, 2019 March 18, 2019 3 min read Propofol is a short-acting, intravenous sedative-hypnotic that is metabolized by the liver and excreted in the urine as conjugates of 2,6-diisopropyl-1,4 quinol. The pharmacokinetics of propofol favor its use for the induction/maintenance of anesthesia (...) with other causes of immunocompromise, especially in those with solid organ or liquid transplants, chronic steroid use, chemotherapeutics, and other immunosuppressive medications. As the use of immunosuppressive agents has increased in recent years, so has the rate of non-HIV associated Pneumocystis pneumonia (PCP). The use of steroids in HIV-infected patients with PCP has been well established, but the role of steroids in HIV-uninfected patients is much less clear. Patients with PCP who are not infected

2019 Clinical Correlations